Results from the pivotal Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a statistically significant...

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive...

Genentech, a member of the Roche Group announced completing the submission of a supplemental Biologics License Application to the FDA...

Bausch Health Companies Inc.and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced that...

Ascyrus Medical, a privately-owned medical device company focused on innovative treatments for aortic dissections, announced the CE mark approval of...

Johnson & Johnson announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4...

Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer...

Merck Inc., announced the presentation of interim data from the Phase 1b/II KEYNOTE-365 umbrella trial investigating Keytruda, Merck’s anti-PD-1 therapy,...

Lundbeck and Otsuka Pharmaceutical announce that data from two global Phase III clinical trials evaluating the safety and efficacy of...

Boehringer and Eli Lilly announced phase III trial CAROLINA met its primary endpoint, defined as non-inferiority for Tradjenta (linagliptin) versus...